Active Ingredient History
Efalizumab is a formerly available medication designed to treat autoimmune diseases, originally marketed to treat psoriasis. As implied by the suffix -zumab, it is a recombinant humanized monoclonal antibody administered once weekly by subcutaneous injection. Efalizumab binds to the CD11a subunit of lymphocyte function-associated antigen 1 and acts as an immunosuppressant by inhibiting lymphocyte activation and cell migration out of blood vessels into tissues. Efalizumab was associated with fatal brain infections and was withdrawn from the market in 2009. Wikipedia
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Alopecia (Phase 2)
Arthritis, Psoriatic (Phase 1)
Arthritis, Rheumatoid (Phase 2)
Autoimmune Diseases (Phase 1/Phase 2)
Choroidal Neovascularization (Phase 1)
Dermatitis, Atopic (Phase 2)
Diabetes Mellitus, Type 1 (Phase 2)
Hidradenitis Suppurativa (Phase 1)
Hypoglycemia (Phase 1/Phase 2)
Kidney Failure, Chronic (Phase 1/Phase 2)
Kidney Transplantation (Phase 2/Phase 3)
Lupus Erythematosus, Systemic (Phase 2)
Macular Degeneration (Phase 1)
Macular Edema (Phase 1)
Psoriasis (Phase 4)
Sjogren's Syndrome (Phase 2)
Uveitis (Phase 1)
Wet Macular Degeneration (Phase 1)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
